Comparing two forms of iron supplementation during pregnancy

Efficacy and Adverse Side Effects of Two Forms of Iron in Prenatal Micronutrient Supplements (EASE-Iron): A Randomized Controlled Trial

Not applicable Interventional University of British Columbia · NCT06014983

This study is testing which of two types of iron supplements works better for pregnant people to improve their iron levels and overall health.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment172 (estimated)
Ages19 Years to 42 Years
SexFemale
SponsorUniversity of British Columbia Academic / other
Locations2 sites (Vancouver, British Columbia and 1 other locations)
Trial IDNCT06014983 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to evaluate the efficacy and side effects of two different forms of iron supplementation, ferrous fumarate and ferrous bisglycinate, in pregnant individuals. A total of 172 healthy, low-risk pregnant participants aged 19-42 years will be recruited in Vancouver, Canada, and randomized to receive one of the two iron supplements along with a prenatal multivitamin. Blood and stool samples will be collected at baseline and follow-up to assess iron levels and gut microbiome changes. The findings will help establish better guidelines for iron supplementation in pregnancy to prevent and treat iron deficiency.

Who should consider this trial

Good fit: Ideal candidates are generally healthy, low-risk pregnant individuals aged 19-42 years who are between 13-25 weeks gestation.

Not a fit: Patients with pre-existing medical conditions affecting iron status or those on medications that interfere with iron metabolism may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved iron supplementation practices that enhance maternal and fetal health during pregnancy.

How similar studies have performed: Other studies have explored iron supplementation in pregnancy, but this specific comparison of bioavailable forms is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Pregnant individual (singleton pregnancy)
* 19-42 years of age
* Living in the greater Vancouver area and willing to travel to the University of British Columbia or BC Women's Hospital for study visits
* 13-25 weeks gestation
* Willing to participate and able to provide informed consent

Exclusion Criteria:

* Having a pre-existing medical condition known to impact iron status (e.g., inherited hemoglobin disorder (i.e., sickle cell, hemochromatosis, thalassemia or other structural hemoglobin variant), malabsorptive disorders (i.e., chronic pancreatitis, cystic fibrosis, celiac disease) and inflammatory bowel disease (i.e., Crohn's disease, ulcerative colitis), gastric bypass surgery, atrophic gastritis, advanced liver disease, kidney dialysis)
* Using medications known to interfere with iron metabolism or the gut pathogen equilibrium (e.g., chronic use of proton pump inhibitors, anti-inflammatory agents, non-steroidal anti-inflammatory drugs, antibiotics)
* Having a personal neural tube defect (NTD) history or a previous NTD pregnancy
* Receiving ongoing blood transfusions
* Currently smoking or having smoked in the past 3 months
* Pre-pregnancy body mass index (BMI) ≥30 kg/m\^2
* Allergy to any study supplement ingredients

Where this trial is running

Vancouver, British Columbia and 1 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions PregnancyIron DeficiencyIronNutrition
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.